Opinions+ Archives

Opinions+ By Marc Herant and Jason Brauner

Incentives to spur repurposing of existing generics for novel uses would open a new paradigm in drug R&D

Opinions+ By Nicole Paraggio, Nicole van Poppel and Selen Karaca-Griffin

Reimagining R&D can cut drug development costs from billions to millions

Opinions+ By Neil Dhawan

The future of pharma and health care will come in small (molecule) packages

Opinions+ By Edward M. Kaye

What biotech can learn from past stock market downturns

Opinions+ By Laurent Levy

Building a better on-ramp for health innovation

Opinions+ By Elizabeth Ruzzo

8 reasons ‘move fast and break things’ doesn’t work for health care companies

Opinions+ By Andy Plump

Maintaining trust in science is crucial to public health. Here’s how the biopharma industry can help

Opinions+ By Andrei Iancu and David Kappos

Why does the FDA want to stop improving medicines via patent ‘areas of concern’?

Opinions+ By Tom Denwood and Scott Kollins

Rewriting the playbook for digital therapeutics

Opinions+ By Andrea Bastek

Combating the burnout bottleneck among clinical research workers

Opinions+ By Dawn Anderson

Digital clinical trials can personalize patient engagement, accelerate therapy development

Opinions+ By Monique K. Mansoura

A 10-point plan for sustaining the biopharma industrial base for a more secure nation

Opinions+ By Chris Plance and Nilesh Chandra

Bringing clarity and consistency to CMS’s hospital price transparency rule will be a win for all

Opinions+ By Bret Schiller

Viruses, variants, and the business of health care: Preparing for another wave now and the years ahead

Opinions+ By Sam Brown

Human-centered design can boost clinical trial recruitment, retention

Opinions+ By Daphne Zohar

Stifling biopharma mergers would kill the innovation economy that generates new therapies

Opinions+ By Stephen Ferguson

SARS-CoV-2 brought the world to its knees. Its digital twin is helping bring us back

Opinions+ By John Freedman

The many benefits of expanding the reach of state all-payer claims databases

patient equation patient friction coefficient

Opinions+ By Raymond Deshaies

‘Induced proximity’ is why I am optimistic about treating undruggable diseases

Opinions+ By Hensley Evans and Sharon Suchotliff

The pharma industry needs to measure patient experience from the patients’ perspectives

Opinions+ By Tonya Winders

Faster approval of complex generics is central to affordable, equitable care

Opinions+ By Shira Machluf

How the FDA’s ‘master plan’ will affect NIH funding for digital medicine projects

Opinions+ By Fiona Gilbert, Mona Flores and Ittai Dayan

Improving health care means improving data diversity. Federated learning can help

Opinions+ By Peter Bak

Investment in antimicrobials was up in 2020, but much work remains

Opinions+ By Giacomo Chiesi

Most Read

Biopharma companies need digital portfolios to succeed in a disease management future

Biopharma’s response to the next pandemic depends on collaboration and the ability to learn and fail fast

How PDUFA VII can catalyze ‘lightspeed’ vaccine and drug development

Manufacturing at the edge: smaller, localized, and agile factories will be key to biopharma drug production

Med tech companies that approach value-based care contracting wisely can earn first-mover advantage

What’s blocking health care boards’ progress in diversity, equity, and inclusion?

Patient engagement: The true benchmark in clinical trials

Forget the hype and embrace the reality: How AI can improve health outcomes right now

All Coverage